| Balance Sheets | 2025-09-30 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 102,577 | |||
| Incentive and tax receivables | 809 | |||
| Prepaid expenses and other current assets | 429 | |||
| Total assets | 103,815 | |||
| Accounts payable | 4,249 | |||
| Accrued liabilities - note 3 | 3,892 | |||
| Deferred grant income - note 4 | 805 | |||
| Total liabilities | 8,946 | |||
| Capital stock authorized 200,000,000 common stock, par value 0.001 per share issued and outstanding 86,668,521 common shares (2024 - 84,795,517) | 87 | |||
| Additional paid-in capital | 477,230 | |||
| Accumulated deficit | -382,448 | |||
| Total stockholders equity | 94,869 | |||
| Total liabilities and stockholders equity | 103,815 | |||
ANAVEX LIFE SCIENCES CORP. (AVXL)
ANAVEX LIFE SCIENCES CORP. (AVXL)